Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
A phase 1/2 trial of TQB2825 in diffuse large b-cell lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.
Overview
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma is a phase 1/2 interventional study registered as NCT06829771 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 90 participants planned, started 2025-04-23 and due to reach its primary completion in 2026-05. Interventions recorded: TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx. Conditions listed: Diffuse Large B Cell Lymphoma. No results are recorded here; the registry entry is the source.
Setting
Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Phase
Phase 1/2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Registry
Enrolled
90